Young adults are showing the highest interest in weight-loss drugs such as Wegovy and Mounjaro, with 48% of the nation’s 18-34-year-olds who are “managing their weight” saying they have either used prescription weight-loss drugs in the past year or are interested in doing so in the future.
This compares with a national average of 30%, according to new research from Mintel.
“Awareness of prescription weight-loss drugs such as Wegovy or Mounjaro is likely higher among young adults due to discussions on social media and media coverage of reported celebrity use of the diabetes drug, Ozempic as a weight-loss solution,” says Mintel Principal Research Analyst – Consumer Lifestyles, Francesca Smith.
Ms Smith says that the “quick-fix weight-loss interest” is also linked with body image anxieties, which are more prevalent in this age group.
“This ‘quick-fix’ weight-loss interest also reflects body image anxieties, which are highest among young adults, with nearly half (49%) of women aged 18-34 saying their body image causes them stress or anxiety,” she explains, adding that brands must act responsibly in this space.
“Brands must avoid capitalising on body image anxieties and continue to promote sustainable lifestyle behaviours, such as exercise and nutritious diets to go alongside any other weight loss methods, and for overall healthy wellbeing,” she says.
“Whilst Wegovy and Mounjaro are currently prescription-only for weight-loss, the increasing availability of related products, such as GLP-1 supplements and meals portioned to match the appetite of someone taking weight-loss medication, highlights the critical need for brands to communicate clearly and responsibly on this topic, including warnings of potential risks and side effects.”
